Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06. (Q43688694)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 April 2013

Language	Label	Description	Also known as
English	Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.	scientific article published on 23 April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

C Villanueva

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G Romieu

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Salvat

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Chaigneau

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Y Merrouche

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

T N'guyen

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Thiery Vuillemin

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Demarchi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Dobi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

23 April 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Targeted oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

137-143

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

https://scigraph.springernature.com/pub.10.1007/s11523-013-0279-4

0 references

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0279-4

21 January 2018

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast cancer in the world: incidence and mortality.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatotoxicity associated with lapatinib in an experimental rat model

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The frequency of cancer in France: mortality trends since 1950 and summary of the report on the causes of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23609057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-013-0279-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23609057%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43688694&oldid=2102525115"